Because fast fatigue NMJs are the first to become disrupted and be eliminated in ALS pathology, we examined Sema3A levels both at P90 and P120 and hypothesized that Sema3A levels will eventually drop in later stages of the disease. This evidence concerns the gene SEMA3A and amyotrophic lateral sclerosis.